Reuters logo
BRIEF-Moleculin to combine brain cancer drug candidate with Roche's Avastin
September 6, 2017 / 11:39 AM / 3 months ago

BRIEF-Moleculin to combine brain cancer drug candidate with Roche's Avastin

Sept 6 (Reuters) - Moleculin Biotech Inc

* Moleculin to collaborate on combining its WP1122 brain cancer drug candidate with Roche’s drug Avastin

* Moleculin Biotech - ‍entered collaborative agreement with University Of Bergen to test WP1122 in combination with drug Avastin made by Roche Pharma​

* Moleculin Biotech Inc - Roche Pharma is not a party to collaborative agreement with University Of Bergen​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below